This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Angiotensin II type 2 receptor (ATGR2)	<p><i>In vitro</i> and mouse studies suggest agonizing ATGR2 could help prevent pain. In a murine cell-based screen of about 8,000 siRNAs, <i>Atgr2</i> was identified as a receptor that mediates the analgesic effect of the mycobacterial toxin mycolactone. In mice, <i>Atgr2</i> knockout prevented mycolactone-induced analgesia. Next steps include developing an ATGR2 ligand to treat pain. Mitsubishi Tanabe Pharma Corp. has the ATGR2 agonist MP-157 in Phase I testing to treat hypertension. At least two other companies have ATGR2 agonists in preclinical development for cardiovascular and pulmonary indications.</p> <p>SciBX 7(28); doi:10.1038/scibx.2014.833 Published online July 24, 2014</p>	Patent application filed; available for licensing	<p>Marion, E. <i>et al. Cell</i>; published online June 19, 2014; doi:10.1016/j.cell.2014.04.040 Contact: Priscille Brodin, Institute Pasteur Korea, Gyeonggi-do, South Korea e-mail: priscille.brodin@inserm.fr Contact: Laurent Marsollier, Institut National de la Santé et de la Recherche Médicale (INSERM) Avenir, Angers, France e-mail: laurent.marsollier@inserm.fr</p>